[News Brief] Johnson & Johnson’s RYBREVANT Combo Sets Landmark Survival Record in Advanced Lung Cancer
Johnson & Johnson’s RYBREVANT plus chemotherapy sets a survival record in Phase 3 PAPILLON trial for EGFR exon 20 insertion-positive…
Pharmaceuticals & Supplements
[News Brief] HUYABIO Reports Positive Phase 3 Results for Advanced Melanoma Therapy
HUYABIO International has announced positive topline results from its global Phase 3 clinical trial evaluating HBI-8000 in combination with nivolumab…
[News Brief] Innovent and Spero License Anti-CD40L Antibody for Autoimmune Diseases
Innovent Biologics and Spero Therapeutics have entered into an exclusive licence agreement for IBI355 (SP001), a Phase 2-ready third-generation Fc-silent…
[News Brief] Fangzhou Launches Once-Weekly Diabetes Combination Therapy in China
Fangzhou Inc. has launched Novo Nordisk’s Kyinsu® on its Internet hospital platform in China, making the once-weekly basal insulin and…
[News Brief] Halozyme and Incyte Partner on Subcutaneous Drug Delivery for Blood Cancer Therapy
Halozyme Therapeutics has entered into a global collaboration and licence agreement with Incyte to develop subcutaneous formulations of INCA033989, a…
[News Brief] Sai Parenterals Renews Australian OTC Supply Agreement
Sai Parenterals’ Australian subsidiary, Noumed Pharmaceuticals, has renewed an exclusive over-the-counter (OTC) medicines supply agreement with one of Australia’s leading…
[News Brief] AstraZeneca Secures Global Licensing Rights to Zegfrovy for Lung Cancer
AstraZeneca has entered into an exclusive global licensing agreement with Dizal Pharmaceutical to acquire worldwide development and commercialisation rights for…
[News Brief] Merck Opens BioReliance Testing Facility in Germany
Merck has opened a 2,000-square-metre BioReliance testing facility at its headquarters in Darmstadt, Germany. The site provides commercial drug substance,…
[News Brief] MAXONA Pharmaceuticals Receives FDA Clearance for Pain Therapy Trial
MAXONA Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application…
[News Brief] Insilico Medicine Initiates Phase III Trial for AI-Discovered IPF Drug Candidate
Insilico Medicine has initiated a Phase III clinical trial evaluating Rentosertib (formerly ISM001-055/INS018_055), an orally administered small-molecule TNIK inhibitor for…